Literature DB >> 20052476

Altered cytokine profiles of mononuclear cells after stimulation in a patient with Blau syndrome.

SangWook Son1, JangHoon Lee, Chan-Wook Woo, IlHwan Kim, YoungChul Kye, KwangChul Lee, JungHwa Lee.   

Abstract

Autoinflammatory Blau syndrome (BS) is associated with NOD2 gene mutations that lead to constitutive NFkappaB activation. NOD2 functions as an intracellular receptor for the muramyl dipeptide (MDP) component of peptidoglycan (PGN). The objectives of this study are to analyse whether NFkappaB activation in BS affects immune cell functions, and whether NOD2 and toll-like receptor (TLR) pathways interact. Peripheral blood mononuclear cells (MNCs) from a BS patient and three normal donors were analyzed for their ability to produce pro- and anti-inflammatory cytokines in the presence and absence of MDP, PGN, and lipopolysaccharide (LPS). The results obtained showed that the basal TNF-alpha and IL-10 production by MNCs over 24 h of incubation was very low for both the patient and the normal donors. However, upon stimulation with MDP, LPS, and PGN, the cells from the BS patient produced much lower levels of TNF-alpha, IL-10, G-CSF, and IFN-gamma than the normal donor cells. We conclude that the pathogenic mechanism responsible for the chronic inflammation that characterizes BS may relate to the impaired production of both pro- and anti-inflammatory cytokines to stimuli. The NOD2 pathway possibly interacts with either the TLR2 or TLR4 pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052476     DOI: 10.1007/s00296-009-1342-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

1.  Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB.

Authors:  Y Ogura; N Inohara; A Benito; F F Chen; S Yamaoka; G Nunez
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

2.  Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation.

Authors:  Nobuo Kanazawa; Satoko Matsushima; Naotomo Kambe; Takao Tachibana; Sonoko Nagai; Yoshiki Miyachi
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

Review 3.  Functional consequences of NOD2 (CARD15) mutations.

Authors:  Clara Abraham; Judy H Cho
Journal:  Inflamm Bowel Dis       Date:  2006-07       Impact factor: 5.325

4.  Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation.

Authors:  Nils Milman; Claus B Andersen; Annette Hansen; Thomas van Overeem Hansen; Finn C Nielsen; Hans Fledelius; Peter Ahrens; Ole Haagen Nielsen
Journal:  APMIS       Date:  2006-12       Impact factor: 3.205

Review 5.  The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders.

Authors:  Naotomo Kambe; Ryuta Nishikomori; Nobuo Kanazawa
Journal:  J Dermatol Sci       Date:  2005-08       Impact factor: 4.563

6.  Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release.

Authors:  Mihai G Netea; Gerben Ferwerda; Dirk J de Jong; Trees Jansen; Liesbeth Jacobs; Matthijs Kramer; Ton H J Naber; Joost P H Drenth; Stephen E Girardin; Bart Jan Kullberg; Gosse J Adema; Jos W M Van der Meer
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

7.  Altered host:pathogen interactions conferred by the Blau syndrome mutation of NOD2.

Authors:  Tae-Hwan Kim; Ursula Payne; Xiang Zhang; Yoichi Iwanaga; Michael P Davey; James T Rosenbaum; Robert D Inman
Journal:  Rheumatol Int       Date:  2006-11-10       Impact factor: 2.631

8.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

9.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation.

Authors:  Olga Gutierrez; Carlos Pipaon; Naohiro Inohara; Ana Fontalba; Yasunori Ogura; Felipe Prosper; Gabriel Nunez; Jose L Fernandez-Luna
Journal:  J Biol Chem       Date:  2002-08-22       Impact factor: 5.157

View more
  8 in total

Review 1.  NLRP12 autoinflammatory disease: a Chinese case series and literature review.

Authors:  Min Shen; Lin Tang; Xiaochun Shi; Xiaofeng Zeng; Qingping Yao
Journal:  Clin Rheumatol       Date:  2016-09-16       Impact factor: 2.980

Review 2.  Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.

Authors:  Ann Marie Szymanski; Michael J Ombrello
Journal:  Int Immunol       Date:  2018-04-25       Impact factor: 4.823

3.  Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.

Authors:  Jae Dugan; Eric Griffiths; Paige Snow; Holly Rosenzweig; Ellen Lee; Brieanna Brown; Daniel W Carr; Carlos Rose; James Rosenbaum; Michael P Davey
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

Review 4.  Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.

Authors:  Tomoko Matsuda; Naotomo Kambe; Riko Takimoto-Ito; Yoko Ueki; Satoshi Nakamizo; Megumu K Saito; Syuji Takei; Nobuo Kanazawa
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

5.  Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency.

Authors:  Zuzana Parackova; Marketa Bloomfield; Petra Vrabcova; Irena Zentsova; Adam Klocperk; Tomas Milota; Michael Svaton; Jean-Laurent Casanova; Jacinta Bustamante; Eva Fronkova; Anna Sediva
Journal:  J Clin Immunol       Date:  2019-11-23       Impact factor: 8.542

6.  A familial case of Blau syndrome caused by a novel NOD2 genetic mutation.

Authors:  Woojoong Kim; Eujin Park; Yo Han Ahn; Jiwon M Lee; Hee Gyung Kang; Byung Joo Kim; Il-Soo Ha; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2016-11-30

7.  Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function.

Authors:  Liming Mao; Atika Dhar; Guangxun Meng; Ivan Fuss; Kim Montgomery-Recht; Zhiqiong Yang; Qiuyun Xu; Atsushi Kitani; Warren Strober
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

8.  T cell-intrinsic role for Nod2 in protection against Th17-mediated uveitis.

Authors:  Ruth J Napier; Ellen J Lee; Michael P Davey; Emily E Vance; João M Furtado; Paige E Snow; Kimberly A Samson; Sydney J Lashley; Brieanna R Brown; Reiko Horai; Mary J Mattapallil; Biying Xu; Michelle C Callegan; Luke S Uebelhoer; Christina L Lancioni; Richard K Vehe; Bryce A Binstadt; Justine R Smith; Rachel R Caspi; Holly L Rosenzweig
Journal:  Nat Commun       Date:  2020-10-26       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.